• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic
  • Guestorial: Demand for Nationalization of Healthcare Services in India
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea
  • Phablecare Raises ₹187 Cr In Funding
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Biotech News - Featured»U.S. Department of Defense Awards Moderna $1.97 Billion COVID-19 Vaccine Contract

U.S. Department of Defense Awards Moderna $1.97 Billion COVID-19 Vaccine Contract

0
By Biotech Express on January 10, 2021 Biotech News - Featured, Biotech News - Industry, SARS- CoV2 & COVID-19 Updates

Printed in January 2021 Issue

The U.S. United States Department of Defense (DOD) awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine. The manufacturing will be handled in Cambridge, Massachusetts and is expected to be fulfilled by June 30, 2021.

Moderna’s vaccine has been granted emergency use authorization (EUA) in the U.S. and in Canada. The EUA was granted by the FDA on December 18 for individuals 18 years of age and older. Health Canada granted authorization on December 23. The Canadian authorization came under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 and was based on a rolling review of data that started on October 12. It included data from the Phase III COVE trial of 30,000 volunteers.

Earlier in December, the Canadian government exercised its option to increase its confirmed order of the vaccine by 20 million doses, bringing the total commitment to 40 million doses.

The European Commission (EC) has secured 160 million doses of Moderna’s vaccine, although the European medicines Agency (EMA) has yet to authorize the vaccine for use in the European Union. A meeting of the EMA’s Committee for Human Medicines (CHMP) is scheduled for January 6, 2021.

The UK government has received a commitment for seven million doses of the Moderna vaccine, 40 million of the Pfizer-BioNTech vaccine, and 100 million doses of the AstraZeneca-University of Oxford vaccine. The Pfizer-BioNTech vaccine is already being distributed in the UK and the U.S. Expectations are that the AstraZeneca-Oxford vaccine will be authorized in the UK on January 4, although there is as yet no indications when or if it will be authorized in the U.S. As of this date, U.S.-based clinical trials of the AstraZeneca-Oxford vaccine have not yet been completely enrolled.

The AstraZeneca-Oxford vaccine was delayed in the U.S. after a clinical hold was placed on the trial after a UK patient suffered a severe reaction, transverse myelitis, a partial paralysis of the spine, that may have been caused by the vaccine. Although the trials restarted after a few days in the UK and other countries, it was delayed for a number of weeks while the FDA evaluated it. There have also been confounding results in the trials, with 1800 participants accidentally receiving a half-dose of the first injection and that group reporting an efficacy of 90%, compared to about 62% in the regular doses. Researchers do not yet understand the disparity.

In the U.S., Moderna has committed to 200 million doses—not including the additional 100 million for the DOD. The company reported on December 11 that the U.S. government had exercised its option to acquire an additional 100 million doses of the vaccine, bringing it up to 200 million. About 20 million are expected to be delivered by the end of this week with the rest available in the first quarter of 2021. The second half of the 200 million will be delivered in the second quarter of 2021.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports

19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea

Phablecare Raises ₹187 Cr In Funding

Leave A Reply Cancel Reply

Current Issue – April 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports April 25, 2022
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows April 24, 2022
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic April 24, 2022
  • Guestorial: Demand for Nationalization of Healthcare Services in India April 24, 2022
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea April 15, 2022
  • Phablecare Raises ₹187 Cr In Funding April 11, 2022
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events April 9, 2022
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers April 8, 2022
  • Bose Institute Scientists earn retraction due to manipulation April 5, 2022
  • WHO suspends Covaxin supply to UN agencies April 4, 2022
  • Lockdowns, Not the Pandemic, Created Havoc April 1, 2022
  • WHO selects Biological E to transfer mRNA COVID vaccine tech April 1, 2022
  • Dr. Reddy’s Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany April 1, 2022
  • New Zealand High Court ENDS Vaccine Mandate: “It’s a Gross Violation of Human Rights” April 1, 2022
  • S&T Ministry to support startup in medical implants March 31, 2022
  • FDA Clears Marketing of Genome-Edited Beef Cattle March 30, 2022
  • Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey March 30, 2022
  • Undisclosed industry payments rampant in drug-trial papers in Australia March 29, 2022
  • Fraud Trial of Former Theranos Executive Ramesh’ Sunny’ Balwani Begins March 29, 2022
  • Substandard, fake medical products increased by almost 47% from 2020 to 2021 during pandemic: report March 29, 2022
  • Editorial: Biofuels in India – a perfect waste to wealth and net zero emission energy option March 29, 2022
  • Bharat Biotech and BIOFABRI partner to develop, manufacture and distribute novel TB vaccine March 28, 2022
  • Fibroheal raises debt funding from BIRAC March 28, 2022
  • Editorial – Energy, Renewable Energy and Bioenergy March 28, 2022
  • IISc, India to set up public health centre with Rs105 cr funding from philanthropist March 27, 2022
  • Tamil Nadu makes scientifically dubious claim on vaccines in the Supreme Court March 27, 2022
  • Guest Article: GENE EDITED-CRISPERED FLOWERS: Blooming with grace March 27, 2022
  • Dr. Anthony Fauci, Biden admin operated with missing data as CDC issued pandemic guidance, emails show March 25, 2022
  • Contents – February 2022 March 3, 2022
  • Drs Ella deserve Padma Award for their innovations and management in biotechnology: India’s pioneer recombinant biologist Prof Ramareddy Guntaka February 26, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • Articles- News Reports
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • BioResearch – Industry
  • Biotech – Agriculture
  • Biotech – Healthcare
  • Biotech – Supplies
  • Biotech News – Featured
  • Biotech News – India
  • Biotech News – Industry
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.